Key points:
·Case Outcome: Philip Morris International (PMI) and its subsidiary Swedish Match have won a collective lawsuit that accused their smokeless tobacco nicotine pouch "Zyn" of overcharging consumers.
·Initiation and Claims of the Lawsuit: The lawsuit was filed in 2024, seeking class action status and damages exceeding $5 million, while also requesting the court to declare the 2022 acquisition of Swedish Match by Philip Morris International (PMI) as illegal.
·Basis of Allegations: The plaintiffs claim that after Philip Morris International (PMI) acquired Swedish Match for $16 billion, they suppressed competition in the market for "modern oral nicotine" pouches, allowing the merged company to raise prices on Zyn, in violation of antitrust laws.
·Judge's Ruling: The judge ruled that the plaintiffs did not provide specific factual evidence of "price changes" or "reduced innovation," and since Swedish Match's market share did not change after the acquisition, they could not prove that the transaction harmed market competition.
·Subsequent Reactions: Philip Morris International (PMI) and Swedish Match welcomed the dismissal of the lawsuit in a statement, saying they are "pleased that this matter has been resolved" and denying any wrongdoing.
·Product and Industry Background: Zyn is the only nicotine pouch product approved by the FDA in the US, sold in small can packaging. Currently, the US is increasing scrutiny on nicotine pouch manufacturers, leading companies to promote traditional tobacco alternatives.
In a recent report by Reuters on September 25, 2025, Philip Morris International (PMI) and its subsidiary Swedish Match have won a collective lawsuit accusing their smokeless tobacco nicotine pouch "Zyn" of overcharging consumers.
David Novak, a federal judge in Richmond, Virginia, stated that the plaintiff failed to provide sufficient evidence to prove that the $16 billion acquisition of Swedish Match by Philip Morris International (PMI) harmed competition in the market for "modern oral nicotine pouches.
The lawsuit filed in 2024 alleges that Philip Morris International (PMI) suppressed market competition after acquiring Swedish Match in 2022, allowing the merged company to raise prices, in violation of antitrust laws.
Philip Morris International (PMI) and Swedish Match welcomed the dismissal of the lawsuit in a statement, stating that they are "pleased that the matter has been resolved.
The plaintiff's lawyer has not responded immediately to a request for comment. Meanwhile, the defendant has previously denied any inappropriate behavior.
Currently, the United States is increasing scrutiny on nicotine pouch manufacturers, leading companies to introduce alternative products to traditional tobacco. This ruling was made in this context. Among them, Zyn is the only nicotine pouch product approved by the FDA in the United States.
Zyn is sold in small cans and comes in a variety of flavors and nicotine strengths.
In this case, consumers are seeking class action status and claiming damages exceeding $5 million, while also requesting the court to declare the merger transaction in question illegal.
In their response to the lawsuit dismissal, the defendant company stated that the lawsuit "only contains conclusory allegations and popular anti-trust terminology, with no factual basis to reasonably suggest that the disputed transaction harmed market competition.
The judge in Norwalk highlighted in the ruling that the plaintiff "did not provide any specific factual basis regarding price changes or reduction in innovation." He also stated that after the acquisition of Swedish Match by Philip Morris International (PMI), the market share of Swedish Match did not change.
The judge ultimately issued a ruling rejecting the request for a "prohibition of re-prosecution," meaning that the plaintiff is not allowed to file a lawsuit again on the same grounds.
We welcome news tips, article submissions, interview requests, or comments on this piece.
Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn
Notice
1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.
2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.
3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.
4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.
Copyright
This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.
For copyright-related inquiries, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.
We welcome any corrections or feedback. Please contact us at: info@2firsts.com
